Bristol

Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million By Reuters

Written by Brendan Pearson (Reuters) - A Hawaii judge on Tuesday ordered Bristol-Myers (NYSE:) Squibb Inc Sanofi (NASDAQ:) to pay more than $916 million to the state for failing to warn nonwhite patients about health risks from the…

Schrodinger gets rights to cancer drug candidate back from Bristol

Investor Empires

koto_feja Bristol-Myers Squibb (New York Stock Exchange: BMI) Rights to its preclinical cancer drug candidate, an SOS1 inhibitor, have been returned to Schrödinger (Nasdaq:SDGR). Schrödinger noted that he had submitted a candidate…

Bristol Myers schizophrenia therapy safe in late-stage trial

Investor Empires

hapabapa/iStock Editorial via Getty Images Bristol Myers Squibb (NYSE:BMY) announced Saturday that its experimental schizophrenia therapy KarXT, acquired as part of its recent Karuna Therapeutics buyout, indicated a well-tolerated…

Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell…

Investor Empires

Bristol Myers Squibb (BMS) has the broadest ongoing cell therapy development program in CD19-positive malignancies with Breyanzi, which also includes trials investigating its use in patients with relapsed/refractory mantle cell lymphoma…